The Mean Corpuscular Volume and Hydroxyurea in Brazilian Patients with Sickle Cell Anemia: A Surrogate Marker of Compliance

Ana Maria Mach Queiroz1, Clarisse Lopes de Castro Lobo1, Emilia Matos do Nascimento2, Basilio de Bragança Pereira3, Claudia Regina Bonini-Domingos1, Gilberto Perez Cardoso1 and Samir K Ballas*

1HEMORIO-State Institute of Hematology Arthur de Siqueira Cavalcanti, Rio de Janeiro, Brazil
2Federal University of Rio de Janeiro, COPPE - Postgraduate School of Engineering, Rio de Janeiro, Brazil
3Federal University of Rio de Janeiro-School of Medicine, Rio de Janeiro, Brazil
4UNESP - Sao Paulo State University, Department of Biology, Hemoglobin and Hematologic Diseases Genetic Laboratory, Sao Paulo, Brazil
5UFF - Fluminense Federal University, Department of Clinical Medicine, School of Medicine, Niterói, Brazil
6Cardeza Foundation, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA

Abstract

The suppression of erythropoiesis by Hydroxyurea (HU) therapy is associated with increase in mean corpuscular volume, in addition to the increase in Hb F. Monitoring the mean corpuscular volume values and the presence of macrocytosis are effective tools of adherence to the treatment with HU in patients with sickle cell anemia. The aim of this study is to monitor the mean corpuscular volume values after starting treatment with HU to determine if macrocytosis can be used as a surrogate marker of compliance with therapy. We conducted a prospective cohort study over one year with measurements of blood counts and mean corpuscular volume after starting therapy with HU in 95 patients with sickle cell anemia who were regularly followed in our ambulatory outpatient unit. In one-year of successful use of HU the mean value of the mean corpuscular volume increased significantly. The Andersen and Gill model demonstrated that the increase of one unit of MCV implies a 5% reduction in the risk of visiting the emergency room. Monitoring mean corpuscular volume values after prescribing HU alerts the provider of noncompliance in order to counsel the patient in question for better adherence to the use of HU that could improve the quality of care and to reduce morbidity and the frequency of acute pain crises and associated healthcare costs.

Keywords: Sickle cell anemia; Hydroxyurea; Compliance; Mean corpuscular volume

Introduction

Sickle cell anemia (SS) is an inherited chronic inflammatory and degenerative disease in which hemoglobin S (Hb S) is produced. Deoxy Hb S polymerizes and initiates a series of pathophysiologic events including decreased deformability of RBC, vaso-occlusion and tissue damage due to ischemia [1]. The phenotypic expression of the disease varies with mild to severe depending on the specific genotype, gene modifiers, epigenetic and psychosocial factors [2]. In its severe form, the disease is characterized by recurrent acute painful crises, severe anemia and organ damage. The recurrent painful episodes often require treatment in the emergency room or the hospital thus interfering with the quality of life of affected patients [3]. These complications of SS usually manifest themselves around the age of 6 months when the synthesis of the sickle β globin chain reaches adult values and continue through the life span of the patient with progressive severity [4-6].

Treatment of patients with SS with Hydroxyurea (HU) has been shown to decrease the frequency of painful crises and acute chest syndrome significantly in addition to other salutary effects such as decreasing mortality and decreasing the frequency of blood transfusion. The exact mechanism of action of HU is not known although the induction of Hb F synthesis and macrocytosis seem to be apparent possible mechanisms [7-10]. Unfortunately compliance with the specific instructions of treatment by the patients has been inadequate. Having an objective marker of compliance by the patients is highly desirable.

The aim of this study is to monitor the Mean Corpuscular Volume (MCV) values after starting treatment with HU to determine if macrocytosis can be used as a surrogate marker of compliance with therapy. A survival model with recurrent events was used to achieve this objective. This model may be used as a tool that allows a multidisciplinary follow-up of the clinical outcome of patients taking HU. This multidisciplinary approach combined with monitoring the MCV values by a physician and a pharmacist will enable a better understanding of the reasons associated with the patients’ failure to comply with the prescribed therapy. Moreover, this may generate better approaches to rational use of HU.

Methods

We evaluated 95 patients with Sickle Cell Anemia (SS) with no coexistent alpha or beta thalassemia who were started on HU and followed regularly in the outpatient unit, from February 01, 2010 to February 01, 2011. From these patients, 44 (46.3%) were males and 51 (53.7%) were females. Their median age at entry was 27 years (mean 31 ± 13). The age range was 13 to 61 years. They were divided into three age groups: under 26 years (43 patients), 26 to 45 years (34 patients) and over 45 years (18 patients). All patients were treated with HU 15 mg/kg/day.

Serum ferritin, folate and B12 were determined by routine approaches to rational use of HU.

Copyright: © 2013 Queiroz AMM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
laboratory methods and they were all within normal limits. Complete blood counts, reticulocyte count, lactate dehydrogenase, ALT, AST and serum creatinine were determined twice per month.

**Statistical Analysis**

Survival analysis generally assumes that survival times of individuals are independent. However, there are cases where this assumption may not be valid. Studies on individual subjects with recurring events during the observation period show a multivariate survival model. In these situations, it is reasonable to consider that there is dependence between the survival times of each individual. The model usually used to describe a possible association between multiple survival times for each individual is referred to as Frailty which is an extension of the Cox proportional hazards model [11]. In that model, a random effect (frailty) is introduced into the risk function as a multiplicative factor.

Box plots were used in this work to verify the difference between the measured values of the MCV before and after therapy with HU for each patient.

The Anderson & Gill (AG) model and the Poisson regression model were evaluated with different outcomes and the same set of covariates [12]. The AG model was used for analysis of recurrent events, where the outcome was the time elapsed until the occurrence of a subsequent ED visit. Three models were considered: the first model used gender, age, the initial MCV and the final MCV as independent variables; the second model used gender, age and the value obtained by the difference between initial MCV and final MCV and the third model used gender, age and the dichotomization of this difference (1 if final MCV is less than initial MCV, 0 if otherwise). The Poisson regression model was also employed to investigate the association between the number of ED visits as the outcome and the initial MCV, final MCV, gender and age as independent variables. The implementation was done using the R Development Core Team software [13].

**Results**

During the study there were no significant changes in liver and kidney function tests. In one-year of successful HU use the mean value of MCV changed significantly (p<0.001) from 92.76 to 99.77 as shown in Figure 1.

According to the AG model the increase of one unit of MCV implies a 5% reduction in the risk of visiting the emergency room (p<0.001). The application of AG model considering the difference between the final MCV and initial MCV as a single explanatory variable (Table 1) confirms the previous result (p<0.001). Dichotomization of the difference of MCV (1 if final MCV is less than initial MCV, 0 if otherwise), the risk of visiting the emergency room is about 3.6 times greater for the group that did not respond to treatment because of the MCV reduction (95% CI=2.237-5.846, p<0.001).

All covariates in Poisson model (Table 2) were statistically significant (p<0.05). The Poisson regression model also showed that the increase of one unit in the positive difference between initial MCV and final MCV resulted in a reduction of approximately 6% in the number of ED visits.

Figure 2 shows Kaplan-Meier estimate and cumulative risk. Patients were divided into two groups, according to treatment response based on the increase in MCV (final MCV-initial MCV) or the decrease in MCV (final MCV-initial MCV). The log-rank, Prentice-Peto and Tarone-Ware tests demonstrated that there is a significant difference (p<0.001) between the time to next ED visit [14-18].

---

**Table 1: Anderson & Gill models.**

<table>
<thead>
<tr>
<th>Model 1 MCVini</th>
<th>Estimate</th>
<th>Std.Error</th>
<th>z</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Intercept)</td>
<td>0.76</td>
<td>0.21</td>
<td>3.66</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MCVini</td>
<td>-0.0511</td>
<td>0.0248</td>
<td>-3.403</td>
<td>0.0007</td>
</tr>
<tr>
<td>MCVdiff</td>
<td>-0.06</td>
<td>0.01</td>
<td>-6.38</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Gender</td>
<td>-0.33</td>
<td>0.15</td>
<td>-2.14</td>
<td>0.03</td>
</tr>
<tr>
<td>Age</td>
<td>0.01</td>
<td>0.01</td>
<td>2.32</td>
<td>0.02</td>
</tr>
</tbody>
</table>

**Table 2: Poisson Regression Model.**

<table>
<thead>
<tr>
<th>Estimate</th>
<th>Std. Error</th>
<th>z value</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCVini</td>
<td>0.21</td>
<td>3.66</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MCVdiff</td>
<td>-0.06</td>
<td>-6.38</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Gender</td>
<td>-0.33</td>
<td>-2.14</td>
<td>0.03</td>
</tr>
<tr>
<td>Age</td>
<td>0.01</td>
<td>2.32</td>
<td>0.02</td>
</tr>
</tbody>
</table>

**Discussion**

Sickle cell disease is an inherited disease affecting 0.1 to 0.3% of the black Brazilian population. It is estimated that hemoglobin disorders, including thalassemia and sickle cell disease, affect approximately 7% of the world population [20]. The genetic aspects of the disease, ethnic factors, co-inheritance of polymorphisms, socioeconomic and the cultural reality of Brazil, contribute to the health of these patients. In comparison to other chronic diseases, patients with SCD develop several co-morbidities, including emotional aspects. The physical limitations caused by SCD are sources of emotional stress especially for the carrier of the disease, resulting in difficulties in the educational, emotional and social adjustments [21].

Data from the National Newborn Screening Program in Brazil indicate that the prevalence of sickle cell trait (Hb AS) is 2-10%. It is estimated that homozygous SS (Hb SS) represents a public health problem in Brazil [22]. Some data report that 25.2% of children with SCD die before the age of five years if not accurately diagnosed by then.
was checked during each outpatient visit using a verbal questionnaire. The intake of HU demonstrates noncompliance thus alerting the provider that the patient in question overtime. As the confidence interval decreases, the risk of having recurrent crises is less than non-compliant patients (right panel). The solid line shows the increase in the number of visits to the emergency of a non-compliant patient. The distance between the curves in both panels (p<0.001).

In this study we used the MCV values and Anderson & Gill model as a tool of evaluation for adherence to treatment. The use of this powerful tool in monitoring MCV values after prescribing HU alerts the provider of noncompliance in order to counsel the patient in question for better adherence to the use of HU that could improve the quality of care and to reduce social and healthcare costs.

**Conclusion**

The MCV proved to be a good marker for the adherence to the correct use of HU in SS and may serve as a tool to monitor treatment. The therapeutic efficacy of HU is well proven. Patients who do not properly use HU have no significant change in their MCV values and continue to have frequent painful crises.

**Acknowledgement**

Supported by the Office of the Secretary of Health for the State of Rio de Janeiro and the Brazilian Ministry of Health

**References**